Twisted Tale: MD Charged In Medicaid Drug Fraud Scheme Once Helped Drug Users
In the profile of her in 1998, Williamson was quoted as being passionate about her work with drug users who had AIDs. She talked about her techniques in helping patients, and the article noted, "her approach works; less than a year into her tenure, many clients are drug-free."
The recent Department of Justice statement alleged that Williamson's world was anything but drug-free.
Williamson allegedly wrote oxycodone prescriptions to patients who had no legitimate need for the medication, while a co-defendant recruited people to obtain prescriptions from her, between September 2009 and August 2010. The other co-defendants worked as resellers, providing the prescriptions to third parties, according to prosecutors.
In one instance, Williamson was in her Manhattan office, and asked for a blood sample from a patient, who unbeknownst to her was an undercover agent. The agent indicated a fear of needles. So, according to prosecutors, Williamson drew blood from another person, put the undercover agent's name on it, and then wrote a prescription for 120 Oxycontin 80 mg pills, according to U.S. attorney's complaint. Williamson was paid $1,500. Each pill was valued at between $30 and $40 on the street.
The arrest of Williamson has spurred debate in New York. A woman whose brother was a patient of Williamson, told the New York Daily News: "Who knew stuff like this happened? She's an upstanding lady! An upstanding lady who peddles drugs! Whew, what a scene!"
- As Medicare Advantage Cuts Loom, Disagreement Over Program's Stability
- Medicare Advantage Carriers See 'No Choice' But to Accept Cuts
- Centralizing the Revenue Cycle Protects the Bottom Line
- CA Fines 8 Hospitals for Medical Errors
- Physicians to Appeal 'Docs v. Glocks' Ruling in FL
- Doctors Feel Pressure to Accept Risk-based Reimbursement
- Surgical Checklists Unused in 10% of Hospitals, CMS Data Shows
- Employers Weigh Risks, Benefits of Private Exchanges
- 3 Management Lessons from a Supermarket Debacle
- A Fresh Look at End-of-Life Care